logo
AI Icon𝛼SK or Search
ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

367
Analysis
Health Care • China
Shanghai Henlius Biotech is a global, innovation-driven biopharmaceutical company focused on delivering high-quality, affordable biologic therapies for oncology, autoimmune diseases, and ophthalmic diseases. The company is engaged in biopharmaceutical research and development, manufacturing, and commercialization, offering products such as the biosimilars HANLIKANG (rituximab), HANQUYOU (trastuzumab), HANDAYUAN (adalimumab), and HANBEITAI (bevacizumab), as well as the innovative biologic HANSIZHUANG (serplulimab). Headquartered in Shanghai, China, the company was founded in 2010.
more
Company Event • 19 Mar 2027 18:15 • Upcoming
Add To Calendar

H2 2026

Company Event • 21 Aug 2026 19:15 • Upcoming
Add To Calendar

H1 2026

Company Event • 20 Mar 2026 18:15 • Upcoming
Add To Calendar

H2 2025

Company Event • 16 Jan 2026 06:45 • Latest

44th Annual J.P. Morgan Healthcare Conference

Company Event • 25 Aug 2025 16:00 • Upcoming
Add To Calendar

H1 2025

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x